In this context, T-cell infiltration of the tumor bed following NACT is a key immune modulator that is useful for determining treatment options for breast cancer, particularly for human epidermal growth factor receptor 2 (HER2)-positive and triple-negative subtypes [5]. This evidence concerns the gene ERBB2 and breast carcinoma.